Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179069 · ClinicalTrials.gov registry record · Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A Phase 1 study of SCLC, sponsored by Zai Lab (Shanghai) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT06179069: Recruiting Phase 1 study of SCLC, sponsored by Zai Lab (Shanghai) Co..
NCT06179069 is a Phase 1 study of SCLC that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 112 participants, below the 184-participant average among 10 other SCLC trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 20 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06179069, a Phase 1 study of SCLC, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Primary Outcome
Number of subjects with Dose Limiting Toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG ZL-1310
Study Locations (20)
California
- Zai Lab Site 2005 - Duarte
Connecticut
- Zai Lab Site 2030 - New Haven
Florida
- Zai Lab Site 2026 - Sarasota
Michigan
- Zai Lab Site 2013 - Detroit
New Jersey
- Zai Lab Site 2001 - Hackensack
New York
- Zai Lab Site 2002 - Buffalo
North Carolina
- Zai Lab Site 2018 - Durham
Ohio
- Zai Lab Site 2024 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
What NCT06179069 shows while recruiting
NCT06179069 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 184-participant average among 10 other SCLC trials with a reported enrollment target (39% lower).
The record links to 1 condition, with SCLC appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT06179069 names 20 study sites across 20 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT06179069 about?
NCT06179069 is a clinical study titled "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer". An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
What is the current status of trial NCT06179069?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2024-01-23. Estimated completion is 2027-07-31.
What conditions does trial NCT06179069 study?
This clinical trial studies the following conditions: SCLC.
What interventions are being tested in trial NCT06179069?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), ZL-1310 (DRUG).
Who is sponsoring clinical trial NCT06179069?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06179069 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06179069's enrollment target sits among peer trials
112 7th of 10 higher than 4 of 10 other SCLC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral MRT-2359 in Selected Cancer Patients
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI